CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider

Core Insights - CorMedix Inc. has entered into a multi-year commercial supply contract with a leading midsized dialysis provider for its product DefenCath® [1][2] - DefenCath® received NDA approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs on November 15, 2023, and began commercialization in inpatient settings on April 15, 2024, with plans to expand to outpatient dialysis clinics in July 2024 [2][3] - The agreement will provide access to DefenCath® at over 500 dialysis facilities nationwide, aiming to reduce catheter-related bloodstream infections for potentially thousands of patients [2][3] Company Overview - CorMedix Inc. is focused on developing and commercializing therapeutic products for life-threatening conditions, with a primary focus on DefenCath® [3] - The company aims to establish long-term relationships with dialysis providers committed to innovation and infection reduction [2][3] - Future plans include developing DefenCath® as a catheter lock solution for other patient populations [3]